Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Design of STEADFAST Study Evaluating TX200-TR101: A Chimeric Antigen Receptor (CAR) T Regulatory Cell Therapy for Living Donor Renal Transplant Recipients

Download PDF